Scholarlink

<p>Preventing secondary influenza transmission in households is challenging, as antiviral prophylaxis is constrained by cost, access and resistance concerns. Lianhua Qingwen (LHQW), an over-the-counter traditional Chinese medicine with reported antiviral and immunomodulatory activity, may represent an accessible alternative for household influenza prophylaxis. Here, in this multicentre, randomized, double-blind, placebo-controlled trial conducted at 55 centres in China between November 2023 and March 2024, we enroled 556 laboratory-confirmed index influenza cases and 1,428 influenza-negative close contacts. Close contacts were randomized 1:1 to receive LHQW (4 × 0.35-g capsules, three times daily for 5 days) or placebo and were followed for 9 days with serial real-time PCR testing. The primary end point was a reduction in the risk of secondary influenza infection among close contacts. The trial met its primary outcome. Secondary influenza infection occurred in 53 of 728 contacts (7.28%) in the LHQW group and 104 of 700 (14.86%) in the placebo group (odds ratio, 0.33; 95% confidence interval, 0.17–0.61; <i>P</i> &lt; 0.001). Risk reduction was consistent across prespecified subgroups, including age, sex, antiviral use in index cases, symptom-onset timing and high-risk contacts. Adverse events were infrequent and comparable between groups, with no severe events reported. (<a href="https://www.chictr.org.cn/showproj.html?proj=203101">ChiCTR2300074385</a>).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The traditional Chinese medicine Lianhua Qingwen in preventing secondary household transmission of influenza: a randomized, double-blind, placebo-controlled trial

  • 期刊论文

  • 发表日期：

    2026年6月26日

查看全文
  • Yangqing Zhan,
  • Zhengshi Lin,
  • Zhonghao Fang,
  • Benjamin J. Cowling,
  • Shiwei Liang,
  • Min Wang,
  • Chunling Zhang,
  • Zongxiang Li,
  • Zhenhui Zhang,
  • Cui-ling Feng,
  • Jiqian Fang,
  • Nancy H. L. Leung,
  • Yuelin Chen,
  • Guofeng Zhou,
  • Yaguang Shi,
  • Lei Peng,
  • Zhougui Ling,
  • Xiaoli Hu,
  • Bojun Chen,
  • Jie Shi,
  • Shaofeng Zhan,
  • Bing Mao,
  • Kun Zhao,
  • Yonghong Chen,
  • Jie Yi,
  • Nanshan Zhong,
  • Zifeng Yang

摘要

Preventing secondary influenza transmission in households is challenging, as antiviral prophylaxis is constrained by cost, access and resistance concerns. Lianhua Qingwen (LHQW), an over-the-counter traditional Chinese medicine with reported antiviral and immunomodulatory activity, may represent an accessible alternative for household influenza prophylaxis. Here, in this multicentre, randomized, double-blind, placebo-controlled trial conducted at 55 centres in China between November 2023 and March 2024, we enroled 556 laboratory-confirmed index influenza cases and 1,428 influenza-negative close contacts. Close contacts were randomized 1:1 to receive LHQW (4 × 0.35-g capsules, three times daily for 5 days) or placebo and were followed for 9 days with serial real-time PCR testing. The primary end point was a reduction in the risk of secondary influenza infection among close contacts. The trial met its primary outcome. Secondary influenza infection occurred in 53 of 728 contacts (7.28%) in the LHQW group and 104 of 700 (14.86%) in the placebo group (odds ratio, 0.33; 95% confidence interval, 0.17–0.61; P < 0.001). Risk reduction was consistent across prespecified subgroups, including age, sex, antiviral use in index cases, symptom-onset timing and high-risk contacts. Adverse events were infrequent and comparable between groups, with no severe events reported. (ChiCTR2300074385).